although other expect would post solid result
favor y/i comp improv growth trend execut high
qualiti mdt report surpass expect mani segment
smooth y/i comparison organ revenu growth
mirror trend diabet pain brain therapi best
street estim within segment solid growth big
surpris quarter growth stark contrast
perform seen among peer quarter increas
guidanc organ revenu growth
mind result reinforc notion mid-singl digit revenu
growth like achiev seem procedur healthcar util
continu grow nice mdt tighten focu growth
area pay push forward forecast higher
impress speed compani turnaround increas
growth rate feel current share valuat ntm ep
estim fair consid compani slower growth vs
larg cap group could see share trade higher next year
see upsid support buy rate thu stay neutral
takeaway repeat last quarter post sale
beat busi line diabet star growth
boost adopt minim
guardian connect cgm elsewher spinal cord stimul
endovascular stroke technolog drove strength rtg
despit one peer character market growth mid-to-high
singl digit rang believ market growth like teen
tweak forecast push forecast better
rtg diabet growth model growth
vs previous somewhat off-set increas mazor
dilut china tariff adj ep increas
valuat remain neutral risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
consolid revenu grow report basi
constant currenc basi diabet led strong top-lin beat
constant currenc growth rang spur world-wide
adopt minim system guardian connect cgm system
sugar iq notabl disclos train activ
user rtg segment outperform well particularli brain
pain therapi especi surpris strength pain given
weak neuromod result mdt peer spinal cord stimul revenu
growth back improv
gross margin better forecast increas
sequenti sg spend better model
 spend revenu slightli higher forecast
overal ebit margin ahead forecast constant
help ep adj ep estim
actualsbtig estimate varianceww cardiac rhythm hf cardiac vascular group minim spine restor therapi diabet net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
increas constant currenc revenu growth
better trend seen increas estim currenc
headwind full year report segment
rais revenu forecast better result diabet pain brain
therapi oper margin flow margin
out-performance although clip degre dilut
mazor china tariff ep model
summari factor beat dilut
tariff mazor better underli perform
turn nudg revenu growth estim
year improv trend core busi
medtron rate neutral next twelv month price-to-earnings basi
share trade estim discount large-
cap med-tech peer group howev feel current valuat warrant
given slower growth vs group btig provid price target
neutral-r stock risk rate includ oper margin expans
underli pressur spine market soft emerg
market margin degrad expans new busi line
competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m
exhibit comp tabl large-cap peer
bpsc growth bpsadj net bpsebit bp btig estim compani filingsnewold changentm johnsonjnjund bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
medtron incom eproduct net y/i good gross total oper oper expens adj oper interest expens non-oper expense/ inc pre-tax incom adj net non-controlling adj net incom adjust ep share total net oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
